Immunovant (IMVT) Competitors

Utz Brands (NYSE:UTZ) and Immunovant (NASDAQ:IMVT) are both mid-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Does the media prefer UTZ or IMVT?

In the previous week, Immunovant had 1 more articles in the media than Utz Brands. MarketBeat recorded 7 mentions for Immunovant and 6 mentions for Utz Brands. Immunovant's average media sentiment score of 0.86 beat Utz Brands' score of 0.68 indicating that Utz Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utz Brands	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, UTZ or IMVT?

Utz Brands has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Does the MarketBeat Community prefer UTZ or IMVT?

Immunovant received 61 more outperform votes than Utz Brands when rated by MarketBeat users. Likewise, 76.71% of users gave Immunovant an outperform vote while only 60.00% of users gave Utz Brands an outperform vote.

Company	Underperform	Outperform
Utz Brands	Outperform Votes 51 60.00%	Underperform Votes 34 40.00%
Immunovant	Outperform Votes 112 76.71%	Underperform Votes 34 23.29%

Is UTZ or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Immunovant's net margin of -1.38%. Immunovant's return on equity of 6.16% beat Utz Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utz Brands	-1.38%	6.16%	3.15%
Immunovant	N/A	-53.40%	-48.85%

Do analysts rate UTZ or IMVT?

Utz Brands presently has a consensus target price of $20.42, suggesting a potential upside of 12.58%. Immunovant has a consensus target price of $48.75, suggesting a potential upside of 91.85%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than Utz Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utz Brands	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immunovant	0 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, UTZ or IMVT?

Utz Brands has higher revenue and earnings than Immunovant. Utz Brands is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utz Brands	$1.44B	1.78	-$24.94M	-$0.25	-72.54
Immunovant	N/A	N/A	-$259.34M	-$1.90	-13.37

Do insiders and institutionals believe in UTZ or IMVT?

96.0% of Utz Brands shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 17.0% of Utz Brands shares are owned by insiders. Comparatively, 4.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Utz Brands beats Immunovant on 9 of the 17 factors compared between the two stocks.